ClinicalTrials.gg
RecruitingNCT06493994MYVAL-TAX-TAVRUpdated Jan 3, 2025

Myval TransAXillary Transcatheter Aortic Valve Replacement Multicenter Clinical Registry

An observational study in Aortic Valve Stenosis, sponsored by University of Luebeck. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-03.

Sponsored by University of Luebeck · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.

Planned enrollment
81st of 98
100 · median 300
Started
2025
with 6 others
Observational
98 of 191
22 open now
Primary completion
2027-01
later than 30 of 57 live
Registered
171st of 191
by date

Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 81st largest by planned enrollment of the 98 observational ones that give a count, is one of 7 that started in 2025, is one of 98 observational ones, reaches primary completion later than 30 of the 57 other live ones, and was the 171st registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Aortic Valve Stenosis with a site in Germany, or all of them as a file.
02

Study summary

Study goal is to determine the feasibility, procedural success, safety and potential benefit of the Myval transcatheter heart valve (THV) in patients undergone transaxillary (TAX) transcatheter aortic valve replacement (TAVR).

03

Conditions studied

  • Aortic Valve Stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who were treated with Myval TAVR via TAX access are included in the registry.

The participating centers also provide a retrospective cohort of TAX-TAVR implantations with other TAVR prothesis (e.g. Edwards Sapien XT/3/Ultra, Medtronic Evolut R/Pro, Accurate Neo, Allegra, Portico) to compare the results and outcomes of the MYVAL-TAX-TAVR registry using the Myval THV with other TAVR bioprothesis used for TAX-TAVR. To further improve comparability between groups propensity score matching between the groups will be performed using the following parameters (age, sex, STS score, peripheral artery disease, atrial fibrillation, minimum axillary diameter, moderate/severe axillary tortuosity and moderate/severe axillary, calcification).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has been treatet transaxillary (TAX) with Myval transcatheter aortic valve replacement
  • \<35 kg/m2
  • Ability to give

Exclusion criteria

Exclusion Criteria:

  • History of coronary artery bypass graft and a patent left internal mammary artery (LIMA)
  • Age ≤18 years
  • Patients presenting with pregnancy
  • Patients without
  • Expected \<2 years
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Othertransaxillary (TAX) transcatheter aortic valve replacement

    Study goal is to determine the feasibility, procedural success, safety and potential benefit of the Myval transcatheter heart valve (THV) in patients undergone transaxillary (TAX) transcatheter aortic valve replacement (TAVR).

06

What researchers measure

Primary outcomes

  1. Time until first occurrence

    * Stroke including ischemic or hemorrhagic stroke, * Systemic embolism, * Major bleeding (BARC type 3-5), or Cardiovascular or unexplained death

    Time frame: 30 Days

07

Study locations

1 of 1 sites recruiting
  • Universität zu Lübeck
    Lübeck, Schleswig-Holstein 23538, Germany
    Recruiting
    • Ingo Eitel, Prof. Dr. med. · Contact
    • Thomas Stiermaier, Prof. Dr. med. · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.

Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 24 months is below that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 10, 2024
StartActual
Jan 1, 2025
Primary completionEst.
Jan 30, 2027
CompletionEst.
Jan 30, 2027
Last update
Jan 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06493994
Lead sponsor
University of Luebeck
Collaborators
University Hopsital Schleswig Holstein Campus Lübeck
Responsible party
Prof. Dr. med. Ingo Eitel (Head of the MKII, University of Luebeck) — Principal investigator
First posted
Jul 10, 2024
Start date
Jan 1, 2025
Primary completion
Jan 30, 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Jan 3, 2025

Study contacts

Ingo Eitel, Prof. Dr.
Contact
ingo.eitel@uksh.de
+49451500444501
Roza Saraei, Dr.
Contact
roza.saraei@uksh.de
+4945150044542

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion